Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984084 | 0.86 | SMN1; SMN2 (0.43) | TGFBR1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL10505071 | 0.86 | SMN1; SMN2 (0.43) | TGFBR1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL29716049 | 0.81 | TGFBR1 (0.50) | TGFBR1ALDH1A1TSHRITGB1ITGA4 | |
| SCHEMBL9985663 | 0.81 | TGFBR1 (0.69) | TGFBR1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL9984709 | 0.81 | TGFBR1 (0.69) | TGFBR1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL112331 | 0.80 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL14088106 | 0.80 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL112332 | 0.80 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7098405 | 0.80 | TAS1R3 (0.49) | TGFBR1SMN1; SMN2ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL8955981 | 0.80 | TGFBR1 (0.49) | TGFBR1ALDH1A1TSHRHSD17B10TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737561-A2 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | Juno Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4051402-B1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | C3S2 GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | JUNO THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12522660-B2 | Methods for selection and stimulation of cells and apparatus for same | C3S2 GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12516099-B2 | Processes for generating engineered cells and compositions thereof | JUNO THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4658675-A1 | METHODS FOR NON-VIRAL MANUFACTURING OF ENGINEERED IMMUNE CELLS | C3S2 GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4647493-A2 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Juno Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250297282-A1 | VIRAL-BINDING PROTEIN AND RELATED REAGENTS, ARTICLES, AND METHODS OF USE | JUNO THERAPEUTICS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4615960-A1 | METHODS FOR MANUFACTURING ENGINEERED IMMUNE CELLS | C3S2 GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-20250283037-A1 | METHODS FOR STIMULATING AND TRANSDUCING T CELLS | JUNO THERAPEUTICS GMBH (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20140234873-A1 | APPARATUS FOR PROCESSING A SAMPLE IN A LIQUID DROPLET AND METHOD OF USING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-08-21 | — | — | US | disclosed |
| WO-2013124474-A2 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | STAGE CELL THERAPEUTICS GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| US-8216855-B2 | Method of processing a biological and/or chemical sample | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-07-10 | — | — | US | disclosed |
| US-20100285573-A1 | Apparatus for processing a sample in a liquid droplet and method of using the same | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-11-11 | — | — | US | disclosed |
| US-20090289213-A1 | METHOD OF PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-11-26 | — | — | US | disclosed |
| EP-2102650-A1 | APPARATUS FOR PROCESSING A SAMPLE IN A LIQUID DROPLET AND METHOD OF USING THE SAME | Agency for Science, Technology And Research (SG) | 2009-09-23 | — | — | EP | disclosed |
| EP-1989529-A1 | METHOD OF PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE | Agency for Science, Technology and Research (SG) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063135-A1 | APPARATUS FOR PROCESSING A SAMPLE IN A LIQUID DROPLET AND METHOD OF USING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063136-A1 | APPARATUS FOR PROCESSING A SAMPLE IN A LIQUID DROPLET AND METHOD OF USING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007094739-A1 | METHOD OF PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | CD4, CD69, ICOS | TGFBR1 1255/4885SMN1; SMN2 379/4885KDM4E 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.